How High Will Roku Stock Go?
Streaming software and hardware maker Roku (NASDAQ:ROKU) has seen its…
Buy
55
ONC Quote, Financials, Valuation and Earnings
Last price:
$269.86
Seasonality move
:
15.69%
Day range:
$268.69 - $272.82
52-week range:
$141.31 - $287.88
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.92x
P/B ratio:
8.34x
Volume:
391.8K
Avg. volume:
365.2K
1-year change:
62.06%
Market cap:
$29.2B
Revenue:
$3.8B
EPS (TTM):
-$3.77
Analysts' Opinion
-
Consensus RatingBeOne Medicines has received a consensus rating of Buy. The company's average rating is a Buy based on 15 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $331.97, BeOne Medicines has an estimated upside of 23.12% from its current price of $269.63.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $259.00 representing 3.94% downside risk from its current price of $269.63.
Fair Value
-
According to the consensus of 16 analysts, BeOne Medicines has 23.12% upside to fair value with a price target of $331.97 per share.
ONC vs. S&P 500
-
Over the past 5 trading days, BeOne Medicines has overperformed the S&P 500 by 5.79% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
BeOne Medicines does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BeOne Medicines has grown year-over-year revenues for 12 quarters straight. In the most recent quarter BeOne Medicines reported revenues of $1.1B.
Earnings Growth
-
BeOne Medicines has grown year-over-year earnings for 0 quarters straight. In the most recent quarter BeOne Medicines reported earnings per share of --.
Enterprise value:
27.6B
EV / Invested capital:
6.24x
Price / LTM sales:
6.92x
EV / EBIT:
--
EV / Revenue:
6.61x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-114.72x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$3.5B
Return On Assets:
-6.77%
Net Income Margin (TTM):
-9.4%
Return On Equity:
-11.54%
Return On Invested Capital:
-8.9%
Operating Margin:
0.99%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $1.6B | $2.8B | $4.2B | $751.7M | $1.1B | |
| Gross Profit | $1.3B | $2.3B | $3.5B | $626.7M | $952.3M | |
| Operating Income | -$1.7B | -$1.1B | -$295.7M | -$261.3M | $11.1M | |
| EBITDA | -$1.6B | -$1B | -$116.5M | -$236.1M | $43.9M | |
| Diluted EPS | -$18.46 | -$7.67 | -$3.77 | -$2.47 | -- | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $5.1B | $6.9B | $4.7B | $3.9B | $3.9B | |
| Total Assets | $5.8B | $8B | $6B | $5.7B | $5.8B | |
| Current Liabilities | $1.1B | $1.4B | $1.3B | $1.9B | $2B | |
| Total Liabilities | $1.8B | $2.1B | $1.8B | $2.3B | $2.3B | |
| Total Equity | $4B | $5.9B | $4.2B | $3.4B | $3.5B | |
| Total Debt | $598.1M | $609M | $488.1M | $1B | $923.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$1.8B | -$902.2M | $212M | -$308.6M | $44.1M | |
| Cash From Investing | $1.1B | -$390.9M | -$460.5M | -$209.8M | -$121.9M | |
| Cash From Financing | -$27.6M | $598.6M | -$2.6M | $162.3M | -$33.8M | |
| Free Cash Flow | -$2.3B | -$1.6B | -$240.5M | -$501.6M | -$72.3M | |
ONC
Sector
Market Cap
$29.2B
$33.4M
Price % of 52-Week High
93.66%
46.84%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
62.06%
-37.4%
Beta (5-Year)
0.299
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$263.36
200-day SMA
Buy
Level
$222.87
Bollinger Bands (100)
Buy
Level
227.04 - 260.72
Chaikin Money Flow
Buy
Level
8.2M
20-day SMA
Buy
Level
$249.54
Relative Strength Index (RSI14)
Buy
Level
64.93
ADX Line
Buy
Level
20.5
Williams %R
Neutral
Level
-30.2699
50-day SMA
Buy
Level
$242.23
MACD (12, 26)
Buy
Level
7.74
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
6.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.2124)
Buy
CA Score
(Annual)
Level (-0.253)
Sell
Beneish M-Score
(Annual)
Level (-2.2095)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-0.1189)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene’s revenue.
Stock Forecast FAQ
In the current month, ONC has received 15 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ONC average analyst price target in the past 3 months is $331.97.
-
Where Will BeOne Medicines Stock Be In 1 Year?
According to analysts, the consensus estimate is that BeOne Medicines share price will rise to $331.97 per share over the next 12 months.
-
What Do Analysts Say About BeOne Medicines?
Analysts are divided on their view about BeOne Medicines share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BeOne Medicines is a Sell and believe this share price will drop from its current level to $259.00.
-
What Is BeOne Medicines's Price Target?
The price target for BeOne Medicines over the next 1-year time period is forecast to be $331.97 according to 16 Wall Street analysts, 15 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ONC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BeOne Medicines is a Buy. 15 of 16 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ONC?
You can purchase shares of BeOne Medicines via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BeOne Medicines shares.
-
What Is The BeOne Medicines Share Price Today?
BeOne Medicines was last trading at $269.86 per share. This represents the most recent stock quote for BeOne Medicines. Yesterday, BeOne Medicines closed at $269.63 per share.
-
How To Buy BeOne Medicines Stock Online?
In order to purchase BeOne Medicines stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will The Trade Desk’s Stock Be in 5 Years?
If you stitched together every advertisement The Trade Desk (NASDAQ:…
Is MSTR Stock Fundamentally Misunderstood?
Software firm turned Bitcoin treasury Strategy (NASDAQ:MSTR) has made waves…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 48x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Sell
11
VEON alert for Jun 14
VEON [VEON] is down 18.57% over the past day.
Buy
74
DAVE alert for Jun 14
Dave [DAVE] is down 12.68% over the past day.
Buy
54
DAR alert for Jun 14
Darling Ingredients [DAR] is up 9.12% over the past day.
